Your browser doesn't support javascript.
loading
Antigenic evolution of SARS coronavirus 2.
Mykytyn, Anna Z; Fouchier, Ron Am; Haagmans, Bart L.
Afiliação
  • Mykytyn AZ; Viroscience Department, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Fouchier RA; Viroscience Department, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Haagmans BL; Viroscience Department, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: b.haagmans@erasmusmc.nl.
Curr Opin Virol ; 62: 101349, 2023 10.
Article em En | MEDLINE | ID: mdl-37647851
ABSTRACT
SARS coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, emerged in China in December 2019. Vaccines developed were very effective initially, however, the virus has shown remarkable evolution with multiple variants spreading globally over the last three years. Nowadays, newly emerging Omicron lineages are gaining substitutions at a fast rate, resulting in escape from neutralization by antibodies that target the Spike protein. Tools to map the impact of substitutions on the further antigenic evolution of SARS-CoV-2, such as antigenic cartography, may be helpful to update SARS-CoV-2 vaccines. In this review, we focus on the antigenic evolution of SARS-CoV-2, highlighting the impact of Spike protein substitutions individually and in combination on immune escape.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article